A B S T R A C T
Urea, a marker of uraemic retention in chronic kidney disease (CKD) and of adequacy of intradialytic solute removal, has traditionally been considered to be biologically inert. However, a number of recent experimental data suggest that urea is toxic at concentrations representative for CKD. First of all, at least five studies indicate that urea itself induces molecular changes related to insulin resistance, free radical production, apoptosis and disruption of the protective intestinal barrier. Second, urea is at the origin of the generation of cyanate, ammonia and carbamylated compounds, which as such all have been linked to biological changes. Especially carbamylation has been held responsible for post-translational protein modifications that are involved in atherogenesis and other functional changes. In observational clinical studies, these carbamylated compounds were associated with cardiovascular and overall morbidity and mortality. These findings shed new light on the validity of Kt/ V urea as a marker of dialysis adequacy. Yet, also the views that the kinetics of urea are not representative of the kinetics of several other uraemic retention solutes, and that urea cannot be held responsible for all complex metabolic and clinical changes responsible for the uraemic syndrome, still remain valid. Future efforts to improve the outcome of patients with CKD might be directed at further improving removal of solutes implied in the uraemic syndrome, including but not restricted to urea, also taking into account the impact of the intestine and (residual) renal function on solute concentration.
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I N T R O D U C T I O N
The biological role of urea in chronic kidney disease (CKD) and in the uraemic syndrome remains a matter of debate [1, 2] . The classical way of thinking was for many years that urea, in spite of its worldwide use for the calculation of Kt/V urea as a marker of dialysis adequacy, is a relatively inert molecule that exerts no major toxicity. This hypothesis was nourished by a number of acute animal experiments, mostly from the 19th century, showing no nominal toxic effects for urea [3] , the experience of Johnson et al., who added urea to dialysate at concentrations in excess of pre-dialysis values without a consistent relationship between uraemic symptoms and urea exposure [4] , and two randomized controlled trials (the HEMO and ADEMEX studies) finding no improved hard outcomes in spite of increases in urea removal [5, 6] .
In contrast, a randomized controlled study by Chertow et al. showed a higher Kt/V urea and improved outcomes in patients treated by daily dialysis when compared with those on a standard thrice weekly dialysis regime [7] , a finding that has been cited as a possible indirect clinical argument in favour of the toxicity of urea [3, 8] . However, these positive results are based on a composite of hard and surrogate endpoints, and for daily dialysis may be related to other factors than solute removal such as less hypotensive episodes due to lower body weight gain in between dialysis sessions, or to better removal of solutes other than urea with potential impact on outcomes [9, 10] .
More compelling than these clinical data are a number of recent experimental studies that have suggested that urea, either by itself or via post-translational protein modifications, induces biochemical alterations with a potential impact on outcomes. Of note, whereas most animal or clinical studies mentioned above are either acute experiments or correlate instantaneous urea concentrations to long-term outcomes, all effects that have been found in these novel studies are very likely chronic and cumulative, so that the negative or neutral outcomes mentioned do not automatically support the idea that urea is inert. In this publication, we summarize the most recent studies showing that urea has a biological impact, and subsequently we will try to define the exact meaning of urea and its removal in the context of uraemia, taking into account this novel information.
C H A R A C T E R I S T I C S O F U R E A
Urea is a small water soluble molecule with a molecular weight of 60 g/mol. It contains two nitrogen atoms and is the endproduct of protein and nitrogen metabolism. Urea is the compound with the highest concentration found in the blood of uraemic patients [11] . The serum concentration of urea is expressed either as a molar or as a mass concentration. Serum urea mass concentration is either specified for the complete urea molecule or for nitrogen equivalents [blood urea nitrogen (BUN)] at a ratio of 60/28. The conversion between different units is:
Under normal conditions, BUN ranges from 6.1 to 20.2 mg/dL, which corresponds to urea concentrations of 13-43 mg/dL or 2.2-7.2 mmol/L. BUN levels are markedly increased in CKD patients, reaching in patients with end-stage renal disease, pre-dialysis concentrations that can reach 10 times or more the upper limit of the normal range.
D I R E C T T O X I C I T Y O F U R E A
At the end of previous century, several studies indicated that in renal medullary collecting duct cells, urea instigates a chain of molecular events, such as the induction of early growth response protein-1 (egr-1) and immediate-early gene (IEG) transcription factor [12, 13] (Table 1) . The urea concentrations used in those studies (200 mM) were substantially higher than those observed in CKD, as these studies mimicked the osmolar conditions of kidney medulla, where a high urea gradient is present. Egr-1 subsequently has been linked to the activation of protein kinase C (PKC) and of inositol triphosphate [20] , two entities that activate and regulate several biological mechanisms, among which the inflammatory response [21] .
Zhang et al. [14] subsequently demonstrated that urea treatment of renal medullary cells at concentrations of 100-300 mM upregulated the expression of growth-arrest and DNA-damage inducible gene (Gadd153/CHOP), a transcription factor that is responsive to oxidative stress. This effect was antioxidant sensitive [14] .
A study, sometimes referred to in support of the toxicity of urea [15, 18] , demonstrated that in atherosclerosis-prone apolipoprotein E knock-out mice the group with elevated urea due to experimentally induced CKD showed more prominent atherosclerotic lesions than control animals [22] . This effect was attenuated by the anti-oxidant N-acetylcysteine (NAC) [22] . However, in this study, urea was used as a marker of CKD severity and a tool to select animals for further study of the protective effect of NAC and thus supposedly was not the only uraemic retention solute to be elevated in the CKD group. Hence, based on that study, there are in our opinion no reasons to accept a proven causal link between elevation of urea and the observed vascular lesions. Accordingly, no correlation was found between atherosclerotic plaque area and urea concentration [22] .
Studies on the biological impact of urea at concentrations relevant for CKD appeared, to the best of our knowledge, only since 2010.
The first major breakthrough describing a direct biochemical effect of urea was published by D'Apolito et al. [15] . These authors demonstrated that when 3T3-L1 adipocytes were submitted to disease-specific concentrations of urea, this resulted in radical oxygen species (ROS) production, increased expression of the insulin resistance-related adipokines, retinol binding protein 4 (RBP4) and resistin and increased O-linked b-N-acetylglucosamine (O-GlcNAc) [15] . The latter effect generates a decrease of insulin signal transduction and thus creates a state of insulin resistance [15] . These in vitro changes were matched by those observed in uraemic mice and normal mice infused with urea [15] , while this effect was attenuated by the antioxidant, superoxide dismutase/catalase mimetic [15] .
Trecherel et al. [16] studied the in vitro expression of proapoptotic proteins in human smooth muscle cells, exposed to urea or phosphate. Of both uraemic toxins, only urea caused relevant modifications, which occurred in one of the proteins of the B cell lymphoma-2 (BCL2) family, namely BCL-2-associated death (BAD) promoter, a finding that conforms to alterations observed by the same authors in uraemic mice [16] , and pointing to the potential of urea to induce apoptosis and cell death in smooth muscle cells, a step at play in atherogenesis and progression of atherosclerosis. Of note, BAD has been linked as well to alterations in carbohydrate metabolism [23] .
Vaziri et al. [17] tested the impact of urea on the integrity of the intestinal epithelial barrier. Previous studies by the same authors in CKD or in the presence of uraemic plasma had demonstrated a disruption of intestinal barrier functions, potentially impairing the protection against leakage of intestinal content such as pro-inflammatory endotoxin into the body [24, 25] . Of note, it has been demonstrated that CKD is linked to increased endotoxinaemia even at the pre-dialysis stage [26, 27] . At the molecular level, this derangement was attributed to a decrease in expression of tight junction proteins [24, 25] .
Although uraemic intestinal urea concentration has rarely been studied, in an experiment in dogs it was shown to be as high as in serum [28] . Hence, studies applying CKD concentrations are also appropriate for conditions in the intestinal lumen. The study by Vaziri et al. [17] tested in vitro the electrical resistance of a monolayer of intestinal epithelium as a surrogate of intestinal barrier function in the absence or presence of urea at uraemic concentrations, and urea appeared responsible for a dose-dependent increase in epithelial leakiness. In addition, the expression of the tight junction proteins occludin, claudin-1 and ZO-1 was decreased [17] . Urease, expressed by intestinal U r e a a n d C K D
bacteria, which converts urea to ammonia, worsened this effect [17] (for the role of ammonia, see below).
D'Apolito et al. subsequently assessed whether the same concentrations that had increased ROS production in adipocytes in their previous study [15] , also induced a similar effect in arterial endothelial cells [18] . At a concentration of 20 mM, ROS generation was indeed induced, engendering further downstream from the activation of other potentially pro-inflammatory and pro-atherogenic pathways, such as increased activity of PKC and of the hexosamine pathway as indicated by an increase of O-GlcNAc, increased expression of the leukocyte adhesion molecules vascular cell adhesion molecule-1 (VCAM-1) and monocyte chemotactic protein-1 (MCP-1), accumulation of advanced glycation end products as well as inhibition of glyceraldehyde-3-phosphate dehydrogenase (GADPH) [18] . In addition, the study showed that urea also induced endoplasmatic reticulum stress and inhibition of the anti-atherogenic enzyme prostacyclin synthase [18] . Neutralization of ROS production annihilated these deleterious effects. Although an animal arm of the study demonstrated similar changes in uraemic mice, no data on the direct toxicity of urea administration to animals with normal kidney function was reported in this study [18] , in contrast to the previous publication by the same group on urea toxicity [15] .
Koppe et al. [19] tested the direct impact of urea on pancreatic b-cells. If islets from normal subjects were exposed to urea, and also when normal mice were treated orally for 3 weeks with urea and their islets were subsequently isolated, glucosestimulated insulin secretion was decreased, a finding analogous to what was observed in 5/6 nephrectomized animals [19] . This effect was coupled to an increase in oxidative stress and in protein O-linked N-glucosamine acylation (O-GlcNAcylation), as well as to a disturbance of glucose utilization and phosphofructokinase-1 activity, which together with the impaired insulin secretion could be reversed by inhibiting O-GlcNAcylation [19] . All these data together suggest a direct effect of urea on the 
pancreas, resulting in deficient insulin secretion and impaired glycolysis.
In summary, at least five studies show a direct biochemical effect of urea at uraemic concentrations (Table 1) [15] [16] [17] [18] [19] . Changes to a large extent are linked to insulin resistance, inflammation and vascular damage, which all relate to the early and increased morbidity and mortality of CKD [29] [30] [31] [32] . Biochemical alterations in vitro were similar across different cell lines, for example, endothelium, pancreatic cells and adipocytes. In at least two studies, the in vitro findings were confirmed after oral urea administration or urea infusion to animals with normal kidney function [15, 19] , although these confirmatory experiments were confined to a limited number of parameters. In those animal studies it was not clear whether the effect that was observed was related to the same direct cellular impact as shown in the in vitro studies, or to an effect of urea appearing in the intestine and affecting the intestinal barrier as observed by Vaziri et al. [17] . Whatever the mechanism, all these studies point to a patho-physiological role of urea in uraemia.
U R E A A S A S O U R C E O F C Y A N A T E
Cyanate is a free radical that is in equilibrium with urea. Generally, it is accepted that 0.8% of the molar concentration of urea is converted into cyanate. Probably due to the increased availability of urea, cyanate levels are also elevated in CKD [33] .
The best known and most extensively studied biological activity of cyanate is related to its induction of carbamylation (see below). Some studies, however, also attribute direct biological action (toxicity) to cyanate. Incubation of coronary endothelial cells in the presence of cyanate decreased nitric oxide synthase expression, and increased thrombogenic tissue factor and plasminogen activator inhibitor-1 expression [34] . In mice, administration of cyanate diminished the vasorelaxing response to acetylcholine of aortic rings [34] . All these changes may contribute to the vascular damage of uraemia.
Cyanate also dose-dependently decreased glucose-sensitive insulin secretion in pancreatic islets [19] . A similar effect was observed with urea per se, but the pathways involved in the cyanate-dependent changes were different from those induced by urea, suggesting that both compounds act independently from each other via different mechanisms [19] .
Carbamylation has been recognized as a post-translational modification of amino acid and protein modification leading to a plethora of biochemical alterations (Table 2 ) (as reviewed in [44] [45] [46] ). As shown by experiments in mice, carbamylation can occur in a host of organs, with more substantial accumulation in CKD than in animals with normal kidney function [36] .
Traditionally, urea has been considered the major source of cyanate and hence of carbamylated compounds, such as e-carbamyllysine (homocitrulline). More recently however, Wang et al. [47] reported myeloperoxidase (MPO)-catalysed oxidation of thiocyanate as a novel mechanism to which they attributed greater strength, especially at sites of inflammation and atherogenesis. Thiocyanate has been reported to be abundant in smokers and is also retained in CKD [47, 48] . Corroborating the intrinsic role of this pathway, homocitrulline was markedly increased in atherosclerotic aortas of human MPO-transgenic mice when compared with wild-type animals [47] . In addition, incubation of low-density lipoprotein (LDL) cholesterol with MPO and thiocyanate resulted in cholesterol accumulation and foam cell formation in macrophages and in proliferation of smooth muscle cells [47] .
Carbamylated compounds interfere with organ and body functions through multiple mechanisms. Carbamylated proteins activate mesangial cells into a profibrogenic prototype, with a potential to play a role in the progression of kidney failure [35] . Within this context, the protein modifications related to carbamylation affect long-lived extracellular matrix proteins such as collagen [36, 37] , a process mimicking in accelerated fashion the phenomena of regular aging [37] , and suggesting a long lasting persistence in the body of carbamylated products. These structural collagen changes also imply a functional element. Leukocytes respond in a different way to these carbamylated collagens when compared with the genuine molecules [38] .
Also, LDL is susceptible to carbamylation [39] . In vitro, carbamylated LDL dose dependently induced endothelial cell death and smooth muscle cell proliferation [39] , vascular cell changes of relevance to atherogenesis. In uninephrectomized apolipoprotein E deficient mice subjected to a high fat diet and oral administration of urea, carbamylated LDL increased about 8-fold Collagen Long-lasting structural changes Modification leukocyte response Gorisse et al. [37] Jaisson et al. [38] Ok et al. [39] Low-density lipoprotein Endothelial cell apoptosis Apostolov et al. [40] Smooth muscle cell proliferation Massy et al. [8] Increased atherosclerosis in atherosclerosis-prone mice Molecular mechanisms inducing vascular damage Sun et al. [41] High-density lipropotein Disturbance endothelial repair function Stim et al. [42] Haemoglobin Not evaluated Mun and Golper [43] Erythropoietin Disturbance of erythropoietic response U r e a a n d compared with non-urea consuming animals [40] . After assessment by either intravital echography or post-mortem macroscopic investigation of the aortic wall after Sudan black staining for lipid deposits, the mice with high carbamylated LDL had higher degrees of atherosclerosis [40] . Carbamylated LDL has equally been linked to a variety of molecular alterations leading to vascular damage such as an increase in endothelial adhesion molecules [8] . Also, high-density lipoprotein is carbamylated in CKD and inhibits endothelial repair function [41] .
Haemoglobin is carbamylated in renal failure [42] . Exposure of haemoglobin to urea resulted in a time-dependent modification, especially during the first 9 days [42] . Unfortunately, this study did not assess whether these changes had a pathophysiological impact.
Erythropoietin can be carbamylated by in vitro exposure to cyanate [43] . Compared with unmodified erythropoietin, subcutaneous injection of carbamylated erythropoietin to SpragueDawley rats showed an inadequate erythropoietic impact [43] .
Altogether these experimental data suggest a profound biological influence of protein carbamylation. The question arises in how far these effects are corroborated by clinical data (Table 3) .
In a clinical analysis that was part of the studies by Wang et al. [47] unraveling the thiocyanate-linked pathway of carbamylation, plasma protein-bound homocitrulline was an independent predictor for cardiovascular disease and death in subjects undergoing cardiac catheterization.
In a group of 187 haemodialysis patients who were followed for their outcomes, carbamylated albumin was correlated to mortality within the first year after enrolment and also to timeaveraged BUN, suggesting a potential value of measurement of concentration of carbamylated compounds as an indicator of chronic urea exposure and accumulation [49] . This relationship with mortality and BUN was validated and corroborated in an independent population of 1161 German diabetic dialysis patients [49] . The study also suggested a higher degree of albumin carbamylation with serum amino acid depletion, and the finding of this clinical association was supported by studies in mice on low protein diet, which next to amino acid deficiency, also showed higher degrees of albumin carbamylation [49] . Hence, it could be possible that amino acid carbamylation leads to protein energy wasting by impeding amino acid incorporation into proteins [45] , but vice versa, amino acid depletion could in its turn diminish the protection of regular proteins against carbamylation, by diminishing the possibility to deviate carbamylation to free amino acids that are not incorporated into proteins.
In a more extensive study on the same group of diabetic dialysis patients with follow-up of 4 years, carbamylated albumin was correlated to cardiac stress markers troponin-T and Nterminal pro-B-type-natriuretic peptide (NT-proBNP) and was associated with a history of heart failure and arrhythmia [50] . In addition, it was strongly related to a number of hard cardiac endpoints such as cardiovasular mortality, sudden cardiac death and risk of death from cardiac failure [50] . Statins were mainly beneficial in the patient stratum with low carbamylated albumin [50] .
In an assessment of a cohort of 347 haemodialysis patients, mortality was highest in the tertile with the highest proteinbound homocitrulline concentration [51] . Homocitrulline and urea concentration were correlated although the correlation was weak, suggesting a role for causative factors other than urea, and/or the fact that homocitrulline is the reflection of long-term cumulated urea concentrations rather than of one single instant measurement. In addition, the correlation with urea was markedly stronger than that with any of the other markers of uraemic retention considered [51] .
U R E A A S A S O U R C E O F A M M O N I A
Urea is converted to ammonia by urease, which is expressed by a number of intestinal bacteria [52] . Ammonia is in part converted to ammonium hydroxide, and both compounds lead to an increase of the pH in the intestinal lumen, mucosal irritation and enterocolitis as additional and possibly more important causes of disruption of the intestinal epithelial barrier than the effect of urea per se [17] . In vitro studies evaluating expression of intestinal epithelial tight junction proteins not only showed their depletion in the presence of urea, but also a further decrease when urease, inducing ammonia generation, was added [50] Carbamylated albumin Diabetic haemodialysis patients Troponin-T Post hoc analysis RCT NT-proBNP History of cardiac arrhythmia History of heart failure Cardiovascular mortality Sudden cardiac death Death from congestive heart failure Koeth et al. [51] Protein-bound homocitrulline
Haemodialysis patients Mortality Observational cohort NT-proBNP, N-terminal pro-B-type-natriuretic peptide; RCT, randomized controlled trial.
[17]. AST-120, an oral sorbent that contains charcoal and captures uraemic toxins and their precursors and also ammonia, protects against this disruption of the intestinal barrier function [53] . The production of ammonia and its deleterious effects is further enhanced by a shift in the composition of intestinal microbiota in favour of bacterial families containing urease [54] . The role of urease in ammonia production is stressed in nephrectomized rats, in which intestinal ammonia was reduced by the administration of a urease blocker, acetohydroxamic acid [55] .
D I S C U S S I O N
The data reviewed in the present article compel us to reconsider our current paradigm about the toxicity of urea. What has long been considered as an inert molecule now seems to interfere with a host of biochemical and organ functions, either directly or indirectly via carbamylation and other mechanisms (Figure 1) . One of the most striking aberrations caused by urea is insulin resistance, a mechanism related to cardiovascular morbidity and mortality [31, 32] . If any specific approach were to be developed to selectively decrease urea concentration, assessment of insulin resistance could be a first surrogate outcome to appreciate whether such intervention would be efficient, at the same time definitely confirming in a clinical setting the toxicity of urea, which up to now has mainly been demonstrated experimentally.
Other components that became apparent in playing a role in the negative biological impact of urea are production of ROS and other inflammatory mechanisms. Like insulin resistance, also these elements are linked to cardiovascular damage and mortality, which are all major causes of uraemic morbidity and mortality [29, 30] .
Part of the biochemical impact of urea overlaps with that of carbamylated compounds. Although it is difficult to discern between these two in vivo, the in vitro experiments clearly demonstrate the independent activity of both factors, which does not of course exclude that both can also induce cumulative effects.
CKD in these processes is at the origin of a vicious circle by inducing the progressive retention of urea, cyanate and thiocyanate, which are directly toxic and/or the sources of carbamylated compounds, the activation of MPO, which catalyses carbamylation, and changes in intestinal microbiota and function, which further enhance inflammation (Figure 1) . Some of these processes are additionally promoted by causes of kidney failure or its progression, including smoking, diabetes, obesity and aging, altogether creating a morbid snowball effect. In this way there are several arguments favouring future strategies that would result in better and more consistent removal of urea than what we attain today.
Yet, for the time being, and with the therapeutic arsenal we have available, it is unlikely that it will be possible in the near future to decrease urea selectively. Almost all removal strategies for end-stage kidney disease simultaneously affect a host of uraemic solutes. It is even questionable whether it would be useful to aim for a selective removal of specific uraemic toxins when considering the multiple retention compounds with biological potential [56] [57] [58] [59] . Thus, it seems more logical to enhance the removal of the broad array of uraemic toxins including, but not limited to, urea, by extracorporeal treatment, preserving kidney function or by restraining intestinal generation, if such approaches are costeffective [60] .
It becomes more and more evident that a substantial part of the biochemical impact of uraemia occurs via the intestine as an intermediary. Although the metabolic generation of urea can be considered as quite straightforward because it simply is the endproduct of amino acid metabolism, the gastrointestinal system plays a crucial role by the digestion of proteins at the origin of urea and the generation of ammonia, which in turn contributes to the disintegration of the intestinal barrier. Optional interventions allowing an impact on these processes are protein restriction, combined or not to ketoanalogues, adsorption of intestinal metabolites and modification of intestinal microbiota toward a more favourable microbial content [61] .
As many of the changes depicted in this review may be cumulative and start occurring long before the dialysis stage, efforts might be focused on preventing retention of uraemic toxins including urea and/or their biological impact already at the earlier stages of CKD [60] .
It could be considered to decrease blood urea by creating an intestinal shift in favour of urease-containing microbiota. A number of in vivo and in vitro studies have confirmed this possibility [62] [63] [64] . However, urease transforms urea in ammonia (see above) and thus one toxin into another, which seems less desirable.
The question should be raised again, in view of these novel data, whether Kt/V urea is still a valid marker of dialysis adequacy. Although Kt/V urea has always remained part of our clinical dialysis practice since its development, if only because it may mimic removal of other vital small water soluble compounds like potassium [1] , with the novel data described in this FIGURE 1: Pathways involved in the toxicity of urea. Left side (blue coloured track): cyanate/carbamylation pathway; middle (green colored track): direct toxicity of urea; and right (red coloured track): ammonia pathway. The general elements within these pathways are indicated in black. Processes and conditions are in normal font, compounds are in bold. Not included in the figure is a pathway of carbamylation that is independent of urea, which involves transformation of thiocyanate (increased in smokers and CKD patients) into cyanate by interference of hydrogen peroxide and myeloperoxidase [47] .
U r e a a n d C K D review, the validity of Kt/V urea becomes even more salient. Yet, the paradigm that there is more in uraemic retention and in solute removal by dialysis than what is represented by Kt/V urea also remains as valid as before, as this index does not necessarily grasp the impact of other aspects related to uraemic solute concentration, such as dialyser pore size, solute kinetic behaviour, adsorption, intestinal generation or metabolism [1] . Urea for certain cannot be held responsible for all complex metabolic and clinical changes constituting the uraemic syndrome [1] , which also includes a number of factors such as nutritional and volume status, electrolyte homeostasis, inflammation, blood pressure or left ventricular hypertrophy.
It remains a matter of debate why, if urea is really that toxic, the results of the HEMO and the ADEMEX studies did not show a benefit when Kt/V urea was increased [5, 6] . One of the reasons could be that, since many of the effects summarized in this review are long lasting, damage had become irreversible once urea removal was increased at the dialysis stage, which in addition occurred in prevalent patients, who on average had been on dialysis already for 3.6 years [5] . Second, increasing Kt/ V urea should have had an impact not only on the removal of urea, but of many other diffusible compounds as well, and some of these substances may have been beneficial, so that increasing their elimination might have neutralized the removal of noxious compounds such as urea. Third, specifically for the HEMO study, the 30% increase of Kt/V urea had a much smaller effect on pre-dialysis concentrations of a variety of toxins, including urea, for which a decrease by only 9% was observed [65, 66] . Last but not least, also for the HEMO study, a substantial proportion of patients were on dialysis times of 3.5 h or less, even in the group on high dialysis doses [5] , whereas data from the Dialysis Outcomes and Practice Patterns Study showed that the observational association of Kt/V urea with survival was to a large extent lost when dialysis time decreased to 3.5 h or less [67] .
Urea is only one of the many small water soluble compounds [57] . Other solutes with the same properties are uric acid, oxalate, potassium and several of the guanidines, including asymmetric dimethylarginine and symmetric dimethyl arginine, many of which have been linked to cardiovascular events. It is not really certain whether the kinetics of urea during dialysis are representative for those of the other molecules of the group. For the ones that have been assessed, such as the guanidines, it is not the case [68] .
A recent addition to the group of small water soluble compounds is trimethylamine-N-oxide (TMAO), which was linked to atherogenesis for the first time only in 2011 [69] and recognized as a uraemic retention product even more recently [70, 71] . Although TMAO generally is linked to mortality and cardiovascular events [69, 71] , some studies attribute the mortality linked to TMAO to confounders like kidney dysfunction and poor metabolic control [72] . The question of whether urea kinetics would be representative for those of TMAO remains partially unanswered up till now. However, a study by Hai et al. [73] compared normal renal and dialyser clearances of urea and TMAO. Distribution volumes were also estimated, albeit only based on pre-and post-dialysis concentrations. TMAO normal kidney clearance was substantially higher than that of urea, whereas its dialysis clearance and distribution volume were lower, resulting in a manifold larger proportional increase of TMAO than of urea when end-stage renal disease patients were compared with normal controls [73] .
C O N C L U S I O N
In summary, an increasing number of experimental studies point to the toxicity of urea. This effect is in part direct and in part indirect via the generation of cyanate, carbamylated compounds and ammonia. Observational data suggest the impact of carbamylated compounds on clinical outcomes, but to the best of our knowledge, there are no controlled clinical studies corroborating the toxic effects of urea per se. . G017815N to T.G.) . T.G. is supported from this grant as a doctoral student.
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